CapTemY90 for Grade 2 NET Liver Metastases

Study Number

646120

Phase

Age Group

Adult

Principal Investigator

Purpose

This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.

Check your eligibility for this trial

Check now

Full Title

UPCC 04219: Phase 2 Study of Capecitabine-Temozolomide(CapTem) with yttrium-90 Radioembolization in the Treatment of Patients with Unresectable Metastatic Grade 2 Neuroendocrine Tumors

ClinicalTrials.Gov ID

NCT04339036

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.